Andere talen Apellis Pharmaceuticals, Inc.

Aandelen

APLS

US03753U1060

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
47,93 ^USD	-4,01%		+0,88%	-19,93%

17/04	APELLIS PHARMACEUTICALS, INC. : Wedbush vindt het aandeel niet inspirerend	ZM
09/04	Apellis Pharmaceuticals Insider verkocht aandelen ter waarde van $3.743.605, volgens een recente SEC filing	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results	23/04
Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing	09/04
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/04
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	01/04
Apellis Pharmaceuticals Insider Sold Shares Worth $1,068,161, According to a Recent SEC Filing	21/03
Apellis Pharmaceuticals Insider Sold Shares Worth $564,050, According to a Recent SEC Filing	20/03
Apellis Pharmaceuticals Insider Sold Shares Worth $645,838, According to a Recent SEC Filing	14/03
Apellis Pharmaceuticals Insider Sold Shares Worth $4,297,549, According to a Recent SEC Filing	11/03
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor	11/03
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor	11/03
Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024	11/03
Apellis Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)	07/03
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06/03
Apellis Pharmaceuticals Insider Sold Shares Worth $16,028,706, According to a Recent SEC Filing	05/03
EyePoint Pharmaceuticals Names Ramiro Ribeiro Chief Medical Officer	04/03
Apellis Pharmaceuticals' Q4 Net Loss Narrows, Revenue Increases	27/02
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02
Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q4 Revenue $146.4M	27/02
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results	27/02
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results	27/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Apellis Pharmaceuticals, Inc.

Aandelen

APLS

US03753U1060

Andere talen

Filters